+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07198074

Randomized Trial Comparing Carboplatin, Paclitaxel, Pembrolizumab With or Without Bevacizumab for Advanced or Recurrent pMMR, TP53 Mutated Endometrial Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

255

Participants Needed

306

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying treatments for women with advanced or recurrent mismatch repair protein proficient pMMR and TP53 mutated endometrial cancer. The trial compares the usual chemotherapy drugs carboplatin and paclitaxel, given with or without the immunotherapy drug pembrolizumab, to new combinations that add the antiangiogenic drug bevacizumab. The goal is to see if adding bevacizumab improves the time patients live without the cancer worsening, and overall survival. Participants are randomly assigned to one of three groups. One group receives paclitaxel, carboplatin, and pembrolizumab every 3 weeks for 6 to 10 cycles, followed by maintenance pembrolizumab every 6 weeks for up to 14 cycles. Another group receives paclitaxel, carboplatin, and bevacizumab every 3 weeks for 6 to 10 cycles, then maintenance bevacizumab every 3 weeks for up to 28 doses. The third group receives all four drugs paclitaxel, carboplatin, pembrolizumab, and bevacizumab with the same schedules as above. Throughout treatment, patients have blood and urine samples taken and undergo CT or MRI scans. After completing treatment, participants are followed for up to 5 years with regular visits every 3 months for 2 years, then every 6 months for up to 3 more years. Researchers monitor progression-free survival, overall survival, side effects, and tumor response. Safety is assessed during and up to 90 days after treatment. This long-term follow-up helps evaluate the benefits and risks of adding bevacizumab to the treatment combinations.

CONDITIONS

Brief Title

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here